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ABSTRACT 
Introduction 
This was a secondary data analysis of a prospective cohort of women enrolled in a 
phase III microbicide trial between October 2005 and August 2008. The study aimed to 
assess the pregnancy incidence rates and factors associated with pregnancy in women 
using barrier method and hormonal contraception, enrolled in the trial. 
 
Methods 
A total of 2508 participants were enrolled in the trial and followed up for up to 12 
months. Of these 2437 were included in the pregnancy incidence analysis and 2171 
participants were included in the multivariate analysis. Data on the main exposure, 
contraception, were collected by structured interview. The main outcome of interest was 
pregnancy, which was measured by detection of human chorionic gonadotrophin in 
urine using Quick Vue® test and confirmed by laboratory based testing. The incidence 
rate of pregnancy was calculated as number of pregnancies per 100 women years of 
follow up. Kaplan Meier Survival analysis was used to determine average time to first 
pregnancy. Univariate and multivariate analyses were conducted using Cox regression 
models to asses the factors associated with incident pregnancies. Data was analysed 
using Stata® version 10. 
 
Results 
A total of 2248 women years of follow up were recorded. A total of 238 pregnancies 
occurred resulting in pregnancy incidence of 11 per 100 women-years of follow up (95% 
CI: 9.32 to 12.02). The incidence of pregnancy increased with time in the study; 98 per 
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100 women years of follow up (95% CI: 85.09 to 112.35) in the last 3 months compared 
to 2 per 100 women-years of follow up (95% CI: 0.94 to 2.92) in the first 3 months of 
follow up. Older age and hormonal contraception use were significantly associated with 
a decreased risk of pregnancy. Women 35 years and older were 49% less likely to fall 
pregnant compared to those who were younger than 25 years, adjusted hazard ratio 
(AHR) 0.51(95% CI: 0.30 to 0.88, p=0.016). Women who used hormonal contraception 
had a reduced risk of falling pregnant AHR 0.66(95% CI: 0.46 to 0.94, p=0.02). There 
was no difference between the two types of hormonal contraception (injectable vs oral) 
with respect to pregnancy risk. 
 
Conclusion: 
The incidence of pregnancy increased with time in the study. Women who used 
hormonal contraception and who were older were less at risk of pregnancy. There was 
no significant difference in pregnancy risk by type of hormonal contraception (i.e. oral 
contraception vs injectable contraception) used. 
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1. INTRODUCTION 
1.1. Background 
The acquisition of HIV infection is an endpoint in all HIV prevention trials and recruiting 
people into these trials requires participants who are at risk for HIV infection. Efficacy 
and effectiveness trials of vaginal microbicides as HIV prevention technologies recruit 
young women whose risk of HIV infection also puts them at risk for pregnancy1. Incident 
pregnancy in an efficacy trial of an investigational product, that has not undergone 
safety testing in pregnancy, leads to interruption of the product use and loss to follow up 
in the trial. It may also have implications for the outcome of the pregnancy. This loss to 
follow up may require increasing the sample size, which may already be large in these 
efficacy trials2. Information on different methods of contraception and pregnancy 
counseling is provided to trial participants and some trial sites provide contraception and 
pregnancy testing is done at regular intervals. Despite this, participants continue to fall 
pregnant and high pregnancy rates have been reported in some trial cohorts1,3,4. 
Understanding factors associated with pregnancy in HIV prevention trials will assist in 
developing strategies for pregnancy prevention in the context of HIV prevention trials. 
This analysis aimed to identify risk factors for pregnancy, in order to help with the 
targeting of counseling of potential trial participants.  
 
1.2. Literature review: Pregnancy in HIV prevention trials: 
Some vaginal microbicide trials have experienced rates as high as 64 pregnancies per 
100 person years ( range 16 and 64 per 100 woman years)1. A number of trials testing 
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different vaginal microbicide products and other HIV prevention strategies completed 
recently have reported the following pregnancy rates:  
• Some of the lowest pregnancy incidence rates were reported in the Carraguard 
trial. In the treatment arm 6.6 pregnancies per 100 woman years were reported 
and 8.2 pregnancies per 100 woman years in the control group5. 
• Three randomised placebo controlled trials, Methods for Improving Reproductive 
Health in Africa (MIRA) trial6, HIV Prevention Trial Network (HPTN) 0397 and 
HPTN 0358 reported similar pregnancy incidence rates. The HPTN 039 trial 
which assessed the effect of acyclovir on HIV -1 acquisition in HSV 2 
seropositive women reported pregnancy incidence rates of 13.2 per 100 women 
years of follow up7. Similar pregnancy incidence rates were reported in the HPTN 
035 trial of a vaginal gel  11.3 per 100 woman years8. The MIRA trial which 
tested the diaphragm and gel for the prevention of HIV acquisition in Southern 
African women, reported pregnancy incidence rates of 13.1 % and 13.2 % in the 
intervention and control groups respectively6. 
• The Cellulose Sulfate (CS) trial, which evaluated the safety and effectiveness of 
6% Cellulose Sulfate vaginal gel in preventing vaginal acquisition of HIV, 
Neisseria gonorrhoea and Chlamydia trachomatis infection, enrolled 1398 
women from 3 African and 2 Indian sites. This trial reported pregnancy incidence 
rates of 21.8 in the CS group and 23.1 in the placebo group9. In a parallel phase 
III trial of CS in Lagos, Nigeria10 that enrolled 1644 HIV negative women, the 
pregnancy incidence was 29 and 28 per 100 woman years in the CS and placebo 
groups, respectively . 
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• Another phase III trial evaluating the effectiveness of SAVVY vaginal gel (C31G) 
in preventing acquisition of HIV infection among women at high risk in Ghana 
reported much higher pregnancy incidence rates. This trial enrolled 2142 women 
with mean age of 22.7 years , the pregnancy incidence rates were 42.5 per 100 
person years and 43.7 per 100 person years in the SAVVY and placebo groups 
respectively11 . 
• The highest reported pregnancy incidence rates were in a phase 2 trial 
conducted by Family Health International ( FHI) in three sites (Ghana, Cameroon 
and Nigeria), evaluating the safety and preliminary effectiveness of daily dose 
Tenofivir Disoproxil Fumarate as an oral pre - exposure prophylaxis (PrEP) in 
preventing HIV infection in women . The reported pregnancy incidence was 52 
per 100 woman years12. 
The large number of pregnancies in women participating in HIV vaccine trials suggest 
that, in future, trials looking at high risk women take into account possible pregnancy 
incidence when sample size is determined2;13,14. Even though these trials reported high 
pregnancy rates, the majority did not report or identify any factors associated with 
pregnancy.  
 
1.3. Factors associated with pregnancy: 
Reid et al15 analysed the risk factors associated with pregnancy among 1358 HIV 
negative HSV-2 seropositive women from 3 African countries who had participated in 
HPTN 039 trial7. Oral contraception, injectables and the intra-uterine device (IUD) were 
associated with a decreased risk of falling pregnant, adjusted hazard ratio (AHR) of 0, 
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31 (95% CI: 0.21 to 0.46), 0.13 (95% CI: 0.07 to 0.22) and 0.27 (95% CI: 0.08 to 0.87) 
respectively. Younger age was associated with increased risk of pregnancy15. 
 
Understanding factors associated with pregnancy may also apply to treatment trials 
such as HIV treatment trials. A prospective cohort study by Homsy et al16 analysed 
factors associated with pregnancy in a cohort of 733 women from rural Uganda, who 
initiated antiretroviral treatment (ART). The overall pregnancy incidence was 8.2 per 
100 woman-years, peaking at 11.7 per 100 women years after ART initiation. Younger 
age (HR = 2.71 per 10 year decrease, 95% CI: 2.95 to 3.78, p<0.001), having a body 
mass index (BMI) ≥ 18.5 (HR = 1.09, 95% CI: 1.01 to 1.18, p=0.024) and not using 
condoms consistently in the last 3 months (HR 1.79, 95% CI: 1.02 to 3.13, p= 0.04) 
were independently associated with pregnancy16. 
 
1.4. Pregnancy and safety in clinical trials 
The safety of participants in clinical research is of prime importance. Concerns about 
unknown effects of an investigational agent on a foetus and potential risks to the future 
reproductive capacity of the female participants necessitate caution when enrolling 
women into HIV prevention clinical trials1,2 ,13 Recently completed and current 
prevention trials are testing products that have never been tested in pregnancy or have 
limited data available on safety in pregnancy. Even though active ingredients of most 
candidates are not systemically absorbed, the foetus / embryo may still be exposed due 
to passage of product to the uterus via the cervical canal17.  
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High pregnancy rates in the trials of these investigational products accentuated the 
importance of establishing safeguards to protect the pregnant woman and the foetus1. 
Different trials have adopted different methods to optimize safety. For HIV prevention 
trials, the strategy adopted has been to ensure that the study protocol prevents 
exposure of pregnant women to drug if clinically important harm from the use of the 
product during pregnancy cannot be ruled out.  
Trials prevent exposure to product by either precluding pregnancy among participants 
or prohibiting product use during pregnancy1. A number of safety and efficacy 
microbicide trials9,10,12,18 and other HIV prevention trials15 required that women stop 
using the investigational product when they became pregnant and resume product use 
after pregnancy. Strict implementation of this strategy is not always achievable because 
pregnancies are not identifiable as soon as they occur1. By the time human chorionic 
gonadotropin (hCG) is detected by most pregnancy tests, it is several weeks after 
fertilization19. Wilcox et al, reported that in about 10% of clinical pregnancies, 
implantation occurred after the 1st day of the next expected period. If trial protocols 
suggest testing for pregnancy intermittently it is possible that some pregnancies may 
remain unrecognized for weeks to months after conception. Thus exposure may be 
prolonged by participants who miss their follow up visits and continue to use the 
investigational product for extended periods of time. This strategy will fail to eliminate 
exposure during early gestation, specifically weeks 2 to 6, a time when the foetus is 
most vulnerable to teratogenic effects1. 
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As a result of these safety concerns, some trials attempted to preclude pregnancy 
among enrolled participants by excluding participants who were planning to fall 
pregnant within a certain period9,10,12,18 and or required that participants use a reliable 
form of contraception throughout the duration of their participation in the trial.  
 
Recommendations from a meeting hosted by Family Health International (FHI) on 
pregnancy in microbicide trials held in November 2005 suggested that future vaginal 
microbicide trials must ensure that women have access to contraception either at the 
trial site or are referred to other providers. In addition effective methods of contraception 
such as the IUCD, injectable contraception, implants and in some areas, oral 
contraception must be easily accessible to participants2,14. Implementing this strategy 
does not guarantee success in preventing pregnancy as providing contraception does 
not necessarily mean that participants will use these consistently. In addition 
contraception is not widely used or acceptable in all communities and this could be a 
barrier to use even if sites do provide contraception.  
 
There are a number of factors that are associated with contraception use and uptake, 
including increased level of education, being married, employed, high parity, desire for 
birth spacing and religion3;20,21,22;23,24,25. Kibuuka et al3, described the pattern of 
contraception use in a multi-site phase I/IIa HIV vaccine trial in East Africa. Pregnancy 
during the vaccination period resulted in discontinuation of further vaccination. The 
majority, 58.3%, of enrolled women reported using hormonal contraception. Married 
women were more likely to use hormonal contraception compared to single, separated 
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or widowed women, OR 3.3 (95% CI: 1.34 to 7.93) and less likely to use condoms, OR 
0.3 (95% CI: 0.12 to 0.97).The pregnancy rate was 8.9%. Of those women who became 
pregnant, 78% had reported using hormonal contraception3.  
 
Being employed, a student, having ever been pregnant and number of sexual partners 
in the past 12 months were described as factors associated with contraception use in 
South African youth26 [ AOR 1.8 (95% CI: 1.3 to 2.6), AOR 1.9 ( 95% CI: 1.3 to 2.7), 
AOR 1.9 (95% CI: 1.5 to 2.5), AOR 0.7 (95% CI:0.5-0.9), respectively]26  
 
1.5. Contraception types, efficacy and safety of types. 
The risk of pregnancy among typical users of highly effective contraception i.e IUCD, 
hormonal injections, sterilization and hormone implants, is 3% or less in the first year of 
use27. Oral contraception and barrier methods (diaphragm and condoms) are less 
effective in preventing pregnancy so the use of these methods in clinical trials may be 
limited. Participants on the injectable contraception were found to be less likely to fall 
pregnant compared to those using barrier methods or oral contraception20,15,28. In a 
secondary data analysis of 5224 women enrolled in a prospective cohort study to 
evaluate the association between hormonal contraception and HIV acquisition, Steiner 
et al28 described the pregnancy risk among oral contraception, injectable contraception 
and condom users in Uganda, Zimbabwe and Thailand. The overall 12 month 
cumulative probability of pregnancy for injectable contraception users was lower than 
oral [0.6% (95% CI: 0.3 to 1.0) and 9.5% (95% CI: 8.1 to 11.0) respectively]. Women in 
Thailand experienced lower pregnancy risk with condom use compared to women from 
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Uganda and Zimbabwe [18.4%(95% CI: 11.1 to 25.7), 29.5 (95% CI: 25.7 to 33.4) and 
23% (95% CI: 19.4 to 27.2) respectively]28. 
 
Condoms have been shown to be less adequate in reducing pregnancy, especially in 
women with a high frequency of sex acts1. Skoler et al29, estimated a 12 month 
cumulative probability that a woman engaging in 20 coital sex acts per month will 
become pregnant, was 51%; given a 90% rate of condom use and no other 
contraception29. 
Even though increasing the use of effective contraception in clinical trials has 
advantages in preventing pregnancies, their use presents other challenges by affecting 
trial outcomes. The use of hormonal contraception may alter the susceptibility of vaginal 
and cervical mucosa to the local effects of the study product, which may complicate 
safety assessment1. Injectable hormonal contraception causes non-menstrual bleeding 
which could affect assessment of product safety, making it difficult to assign bleeding as 
product-related in the presence of injectable progesterone. Depot medroxyprogesterone 
acetate (DMPA) may induce heavier, prolonged or irregular bleeding in some women, 
especially in the first year of use. These bleeding side effects could also have negative 
effects on contraception adherence rates30. 
 
1.6. Diagnosing pregnancy in vaginal microbicide efficacy and 
effectiveness trials: sub clinical pregnancies 
Pregnancy in clinical trials should be detected as early as possible to avoid exposure to 
the product whilst pregnant. To ensure this, most trials perform pregnancy tests on a 
monthly basis. More frequent testing could mean that some sub-clinical pregnancies are 
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diagnosed, these are pregnancies that would normally end around the time of a normal 
menstrual period and so would not have been identified in a normal setting1,19. The 
literature suggests that up to 70% of conceptions may be lost prior to term and the 
majority of these occur prior to the time of the missed menstrual period31. Wilcox et al19 
studied the risk of early pregnancy loss by collecting daily urine specimens from 221 
healthy women who were attempting to conceive. The study identified 198 pregnancies 
by an increase in the hCG level near the expected time of implantation. Of these, 22% 
ended before pregnancy was detected clinically. Monthly pregnancy testing may result 
in a higher rate of diagnosis of sub-clinical pregnancies. This could in turn lead to 
unnecessary censoring of women32 from a study and might require larger sample sizes 
for efficacy studies to accommodate this early censoring. 
In the HPTN 039 trial, 59/228 (25.9%) of participants that tested positive for pregnancy 
at follow up, were negative on repeat testing at the next monthly visit, with 41/59 (69%) 
reported as miscarriages15. 
 
1.7. The impact of pregnancy in the interpretation of trial data 
High pregnancy rates in HIV prevention trials pose a number of challenges in 
interpretation of trial data, such as the following: 
1.7.1. Reducing the maximum detectable effectiveness of product and 
power to detect the lower effectiveness level  
The trial’s ability to detect a difference may be affected when pregnant participants stop 
product use, either because product is interrupted or discontinued by the study, or if the 
participants decide to stop using product of their own choice due to pregnancy1. 
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Time off product due to pregnancy adversely affects the study’s power in trials whose 
sample size and power calculations may not account for this time off product. In 
addition, where the possibility of pregnancy is taken into account and higher than 
expected pregnancy rates occur, this will affect the ability of the trial to detect a 
difference between treatment arms1,4;11;33,34,35. 
In the CS trial in Nigeria, pregnancy in both the placebo and CS groups was the primary 
reason for product discontinuation, accounting for 54% of product discontinuations, but 
because many women did not carry pregnancies to term, time off due to pregnancy10 
was only 4.48% of total observed person-time. In the SAVVY Nigeria trial, even though 
the most common reason for product interruption was running out of gel, pregnancy 
caused longer interruptions and accounted for 50% of all observed person-time off 
product, about 5% of total time in both groups36. 
The SAVVY Ghana trial reported the longest time off product use due to pregnancy,  
with the median amount of time off product use, due to pregnancy, being 2 months. This 
resulted in 10% of the total time off product being due to pregnancy11. 
 
Raymond et al1 gave an example to demonstrate the effect of non-use of product on the 
power and study size in a trial that is designed to have 80% power to detect 50% 
effectiveness in reducing HIV acquisition. Assuming product is used 80% of the time 
and where the 12 month cumulative probability of pregnancy is 40% and each 
pregnancy lasts 3 months, then approximately 10% of follow up time off product would 
be due to pregnancy. This scenario would increase the total amount of time off product 
due to pregnancy from 20% to 28%, reduce effectiveness to 45% and increase the 
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number of incident HIV infections required to demonstrate an effect in an intent to treat 
analysis by 33%1 This increase will be a challenge even in countries with high HIV 
incidence.  
Also, in an intention to treat analysis the effect size decreases because pregnant 
women who stop using product have a likelihood of seroconversion that is comparable 
to that of the control group. Censored observations reduce the total number of 
participants left at risk for the event under study37. 
 
1.7.2. Introducing bias in estimating effectiveness 
It maybe possible to introduce bias if there are different pregnancy rates between the 
experimental and placebo groups, for example, if the product being evaluated has 
contraceptive properties. If the risk of HIV acquisition changes with pregnancy as 
suggested by some investigators38, the observed effect could be a result of the 
product’s direct ability to prevent HIV or its indirect impact on changes in HIV risk 
associated with pregnancy1,32.  
Gray et al38 reported higher HIV incidence rate ratios during pregnancy compared to 
non-pregnant and non-lactating women (2.03, 95% CI: 1.33 to 3.11). The HIV incident 
rate ratio was also higher during pregnancy compared to the period of breastfeeding 
(1.76, 95% CI: 1.05 to 2.94)38. 
 
A trial with a product that has a highly effective contraceptive effect but has no direct 
effect on HIV acquisition, could give a result suggestive of effect if the risk of acquiring 
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HIV increases disproportionately in the control group, due to increased pregnancy rates 
in the control group1.  
If on the other hand pregnancy is associated with decreased risk of HIV acquisition, an 
efficacious product that is also contraceptive, resulting in low pregnancy rate in the 
active arm could appear ineffective1. 
 
1.7.3. Sexual behaviour change in pregnancy 
The investigators for the SAVVY Ghana trial did an interim analysis in 2006 that showed 
a change in sexual behavior of pregnant participants. After approximately 75% of the 
expected person-time accrued in the trial, there were 713 women with at least one 
pregnancy. Of these, 636 had self-reported information regarding sexual activity and 
condom use pre- and post-pregnancy detection. The pre-pregnancy mean number of 
vaginal sex acts in the last 7 days was 6.4; the mean dropped to 5.1 at the post-
pregnancy follow-up visit. This difference of 1.3 sex acts (95% CI: 0.88 to 1.67) was 
significant using the Wilcoxon signed ranks test (p<0.001)39.  
A stratified analysis by pregnancy test result at the next follow-up visit also showed that 
the reduction in number of sex acts was greater in women who continued with 
pregnancy. The women who were no longer pregnant at the follow up visit reported an 
average reduction of 0.7 acts (95% CI: 0.22 to 1.27; p=0.009). However, the women 
who were still pregnant at follow up reported an average reduction of 1.9 acts (95% CI: 
1.28 to 2.47; p <0.001). 
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This kind of change in sexual behavior could affect a woman’s risk of acquiring HIV, 
which could in turn lead to statistical issues including loss of study power and difficulties 
in the interpretation of study results. 
The SAVVY Ghana trial subsequently reported a low incidence of HIV (1.09 per 100 
person years, 95% CI: 0.63 to1.74) and was closed prematurely because it would have 
required revision of sample size for it to be adequately powered to show a significant 
difference between the trial arms11.  
 
1.8. Statement of problem: 
Pregnancy in vaginal microbicide trials is an issue because of safety concerns about 
unknown effects of an investigational product to both the pregnant woman and the 
fetus. In addition, high pregnancy rates among women in HIV prevention trials can 
undermine the statistical measures of effectiveness and safety. The number of 
pregnancies in a clinical trial influences the time contributed by the person who is 
pregnant, which affects the outcome and interpretation of the trial results due to a 
change in sample size and power to detect effectiveness. The reduction in use of 
product during pregnancy reduces both the maximum detectable effectiveness of 
product and the power to detect this effectiveness. Therefore, predictors of pregnancy 
are important to explore and document for researchers to maximize efforts to reduce the 
incidence of pregnancy in the trial population.  
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1.9. Justification for the study: 
At a microbicide conference held in Cape Town in 2006, high pregnancy incident rates 
were highlighted as a concern in the conduct of microbicide trials2;14. Interpretation of 
trial results, validity, safety issues, logistics of diagnosing pregnancy, management and 
care of the pregnant participants are some of the issues that have to be considered with 
increasing numbers of pregnancies in these trials2,14;40;40;41. 
As southern African countries are still experiencing high incidences of HIV, countries 
such as South Africa are considered ideal places to conduct trials where HIV acquisition 
is a trial end point. Factors that are locally relevant that may help trials to predict the 
incidence of pregnancy and consequently decrease this incidence, make local data of 
high importance. 
This analysis aims to assess if women using barrier methods and hormonal 
contraception who became pregnant in the trial shared any common characteristics. In 
addition this analysis will attempt to describe differences, in particular type of 
contraception used, between those women who became pregnant on the trial and those 
who did not. If women who became pregnant shared common characteristics, this 
information could be used to help with the targeting of recruitment of potential 
participants and counseling of trial participants. 
 
1.10. Research Question:  
What is the incidence of pregnancies and factors associated with pregnancy in women 
using barrier methods and hormonal contraception who took part in a phase III vaginal 
microbicide trial in Johannesburg? 
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1.11. Null Hypothesis: 
There is no difference in demographic factors, education and partner types between 
women using barrier methods and hormonal contraception who became pregnant and 
those who did not fall pregnant during their period of participation in a phase III 
microbicide trial.  
 
1.12. Objectives: 
• To determine the incidence of pregnancy in participants who took part in a phase 
III vaginal microbicide trial at the Johannesburg site. 
• To describe the factors that were associated with incident pregnancies in women 
using barrier methods and hormonal contraception  
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2. METHODOLOGY 
This chapter details the study methodology which includes an overview of the primary 
study, data collection, data entry, cleaning and methods for analysis. Details of the 
specimen collection methods and testing are also described. 
 
2.1. Research Setting 
The Reproductive Health and HIV Research Unit (RHRU) was one of six partner sites 
that participated in the Microbicides Development Programme (MDP) clinical trial. The 
primary study, the MDP301 trial, was a multicentre randomized double blind placebo 
controlled phase III trial. The primary objective of the trial was to assess the efficacy and 
safety of 0,5% and 2% PRO 2000/5 vaginal microbicide compared to placebo in 
preventing vaginally acquired HIV infection. The 2% arm was discontinued in February 
2008. Between October 2005 and August 2008, the RHRU sites recruited and enrolled 
2508 HIV negative, sexually active women who were 18 years and above. Each woman 
was followed up monthly for a period of up to 12 months. 
 
2.2. Study Design 
This was a secondary data analysis of data collected in the MDP 301 trial. This analysis 
will look at a cohort of women, in a prospective manner, to determine the incidence of 
pregnancy and the risk factors associated with pregnancy in women using barrier 
methods and hormonal contraception. Even though the trial was designed for 12 
months of follow up, of the 2508 women enrolled in the study period, not all women 
would have completed a full year of follow up at the time of this analysis. A total of 2437 
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women completed at least one follow up visit and so were included in the analysis of 
incident pregnancy. 
 
2.3. Study population 
The MDP 301 trial recruited women from Orange Farm and Soweto which are large 
townships south of Johannesburg, South Africa. Women were recruited from local 
primary health care clinics and referred to designated study clinics for screening. 
To be enrolled in the study, women had to be 18 years and above, sexually active at 
enrolment and likely to be sexually active during follow up, willing to undergo HIV testing 
at 12 week intervals (including receiving HIV results), HIV negative at screening, willing 
to use the study gel as instructed and undergo regular speculum examinations and 
screening for genital tract infections, willing to test for pregnancy at monthly visits, 
willing to receive health education on condoms and willing and able to give informed 
consent. 
 
A woman could not be enrolled if she was allergic to latex, likely to have sex more than 
14 times a week on a regular basis, had a grade 3 clinical or laboratory abnormality or 
was participating in another HIV prevention trial. 
Intending to fall pregnant was not an exclusion criterion and women were informed 
during the informed consent process that product use would be discontinued or 
interrupted if they became pregnant during follow up. Participants were counselled on 
effective contraception and initially were referred to local clinics for contraception; later 
in the trial, contraception was provided at the site. 
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Once enrolled, each woman was scheduled for monthly follow up visits and followed up 
for a total period of up to 52 weeks. If a participant missed a scheduled visit, 3 
telephonic contacts and a home visit were made to contact that participant and 
reschedule the visit. These attempts were made for each missed monthly visit. All 
participants who did not return to the study before the end of their one-year follow up 
period were considered lost to follow up. 
2.3.1. Trial Procedures at follow up 
Each monthly follow up visit included an interview, gel collection and pregnancy testing. 
Clinical visits were scheduled at 12-week intervals with a visit window period of 2 weeks 
on either side of this 12-week interval. Clinical visit procedures included HIV and 
pregnancy testing, collection of swabs for STI testing from all participants and bloods for 
the safety profile testing for the first 500 enrolled patients. Participants who were 
symptomatic for STI at any visit were treated syndromically at the visit and those who 
had positive results from STI screening at clinical visits were called back to collect 
treatment. 
2.3.1.1. Gel Use 
Based on their sexual activity, each woman was provided with enough gel supply at 
monthly visits to cover each sexual act until the next visit and was encouraged to come 
back for more gel supplies between visits when necessary. Following the review of data 
accrued by end January 2008, the independent data monitoring committee 
recommended that the 2% arm be discontinued on grounds of futility. Women remaining 
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on 2% arm were withdrawn from gel use but were asked to attend the clinical visits at 
week 4,12,24,40 and 52. 
2.3.1.2. Management of pregnancy outcomes 
At each monthly visit a pregnancy test was conducted and results given to the 
participants. Gel use was interrupted at the time of a positive pregnancy and options 
available were discussed with each woman. Participants who opted to continue with 
pregnancy were scheduled for quarterly visits. Participants who opted for termination of 
pregnancy were referred to a facility that provides termination of pregnancy. Women 
were allowed to resume gel use after a pregnancy was completed, and a pregnancy test 
was confirmed negative . 
2.4. Measurement 
2.4.1. Measurement of Outcome Variable 
The main outcome of interest was pregnancy. Pregnancy status was assessed for each 
enrolled woman on a monthly basis by testing urine using a Quick Vue® rapid test. To 
validate the study site test, 5% of all urine samples tested at the site were sent to the 
reference laboratory, for confirmation using the Quick Vue qualitative one step hCG 
combo test. 
Pregnancy tests at the clinical trial site were performed by the research nurses, who 
were trained in the testing procedure. All positive tests were confirmed with serum 
qualitative hCG tests. 
Time to first positive pregnancy test after enrolment was defined as time to failure. 
Only one pregnancy was considered for each woman. 
pregnancy outcomes was not included in this analysis. 
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2.4.2. Exposure variables  
The main exposure variable was type of contraception used. Contraception use was 
confirmed at each monthly visit, through structured interviews. Type of contraception 
used was classified to oral contraception, injectable (DMPA and Nur-isterate), barrier 
method (male or female condoms, diaphragm), natural rhythm, IUCD and traditional 
methods (oral and other).Only women on hormonal contraception and barrier method 
were included in the regression model. Contraception use at follow up was allocated as 
the type of contraception that was reported by the woman at the visit when pregnancy 
was diagnosed. The analysis did not take into account the change in contraception use 
over time and how long each woman had been on a particular method before they 
became pregnant. 
Time on the study was also considered as a risk factor for pregnancy.  
 
2.4.3. Sources of Bias and Confounders 
Selection bias could play a role as participants for the main trial were volunteers and 
women who chose to participate could be different to the general population. Trial 
targets for follow up were 85% for each visit and women who were lost to follow up 
could be different from those who continued trial participation until the end. The study 
excluded HIV positive women; this group might be systematically different from the HIV 
negative women thus making extrapolation to the general population difficult. 
 
Confounders in the relationship between type of contraception used and pregnancy 
could include age, in that younger women are more likely to consider pregnancy23 and 
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religion as some religions could influence choice of contraception. Additional 
confounders would include level of education, partner type and marital status16;23,25. 
The only possible effect modifier for consideration is the study product, 0.5%, and 2% 
PRO2000/5 gels. If the product had contraceptive properties, this could have affected 
the risk of pregnancy differently between participants on PRO2000/5 and placebo. 
Literature suggests that PRO2000/5 does not have any contraceptive properties 18,42. It 
was therefore assumed that the risk of pregnancy remained the same for participants on 
active product and those on placebo. 
2.4.4. Other Risk Factors 
Data on intercurrent illness like vomiting, that could have interfered with absorption of 
oral contraception was not collected as part of the main trial and was therefore not 
possible to analyse. Data on concurrent medication that could have interfered with 
absorption of oral contraception was not included in the analysis. 
2.5. Data Management: 
2.5.1. Data Collection  
Data were collected through structured interviews by trained research nurses and 
community health workers using case record forms (CRF). Demographic data, which 
included age, employment status, level of education and religion were collected at the 
screening visit. The screening visit was a maximum of 6 weeks before enrolment into 
the study. Data on contraception use and sexual behaviour were collected at the 
screening visit and again at the enrolment visit. Sexual behavior and contraception 
histories were updated at the monthly gel collection visits and at the quarterly clinical 
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visits. Inconsistencies in CRFs were dealt with at the data collection level by research 
nurses who did quality checks on all the forms completed. 
 
2.5.2. Data Entry 
Data for the main trial were double data entered into an MS SQL database. Data were 
verified to see if the two entries were corresponding before saving each record. 
Inconsistencies picked up at data entry were dealt with by raising queries for the clinic 
staff to correct the errors before data entry. Quarterly monitoring visits were conducted 
on the site and a proportion of case record forms were reviewed for accuracy of data 
and to ensure that the study was conducted according to International Conference on 
Harmonization- Good Clinical Practice (ICH-GCP) guidelines. 
 
2.5.3. Staff training: 
To ensure standardized data collection, all the staff members who were responsible for 
data collection and entry received training conducted by the MRC UK’s Clinical Trials 
Unit (CTU) and by the site. Training included interviewing skills, completion of CRFs, 
specimen collection and testing and interpretation of pregnancy results. 
 
2.5.4. Data extraction: 
Four data sets were extracted for this analysis. The data sets comprised of 
demographic data, sexual behavior data, participant follow up and pregnancy results.  
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2.5.5. Data cleaning: 
The MDP database had a number of in-built quality checks that ensured that high 
quality data was produced. Participant’s identification numbers were verified before 
study records were captured, completed CRFs were checked after each visit by quality 
control personnel before being captured. 
After extraction each datatable was individually cleaned. Variables were described, 
tabulated, cross-tabulated, summarized and browsed through to check for 
inconsistencies and outliers. Data cleaning included range checks across data and 
removing extreme values which were biologically implausible. 
The variable “age” was compared to the date of birth variable to confirm if age recorded 
was correct. 
 
2.5.6. Missing values 
Missing values were identified and are reported in the results sections. 
 
2.6. Data processing and data analysis methods 
The data was managed and analysed using STATA® version 10. For the analysis, the 
different datatables were merged into one dataset using the study ID as a unique 
identifier. 
2.6.1. Regrouping of variables 
For the process of data analysis the following regroupings were done: 
Age  
Age was re-grouped into a categorical variable and the categories used were age 18 to 
24 years, 25 to 34 years, 35 to 44 years, 45 years and above. This grouping put 
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younger women, who maybe more likely to fall pregnant, into an appropriate group. The 
age groups 35–44 years and above 45 years were collapsed into one age group, 35 
years and above, because there were very few participants that were aged 45 years 
and over. 
Contraception used: 
Type of contraception used was regrouped into a binary group hormonal contraception 
(oral or injectable) and barrier methods (condoms and diaphragm) for the incidence 
rates for pregnancy by type of contraception used analysis. For the incidence rates for 
pregnancy by type of hormonal contraception used analysis, contraception was divided 
into the binary group injectable contraception and oral contraception as the exposures. 
Level of education: 
This was regrouped to the following categories: No education, completed primary 
education, completed secondary education and completed tertiary education.  
No education was added to the primary education group due to small numbers in the no 
education group. Also, completed secondary education and tertiary were combined into 
one group in the univariate and multivariate analysis due to small numbers in the 
completed tertiary education group. 
Employment status: 
This was regrouped to a binary outcome - employed and not employed. 
 
 
Religion  
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Religion was regrouped into a categorical nominal variable - Christian, Zionist, other 
(Muslim, Shembe, Hindu, Jehova’s witness and African traditional) and None. 
Type of partner was grouped to a binary outcome (long-term stable partner and other). 
 
2.6.2. Descriptive Statistics 
Descriptive statistics were used to describe frequencies and proportions of possible risk 
factors for pregnancy i.e age, type of sexual partner, level of education, employment 
status, religion and type of contraception used in the cohort. The distribution of risk 
factors at baseline was compared between those who became pregnant and those who 
did not. To assess group differences, categorical variables were presented with 
numbers, percentages in each category and a Chi squared or Fishers exact test were 
used, as appropriate, to assess statistical significance. 
 
2.6.3. Analytical statistics 
All results were presented with a significance level and a 95% confidence interval. Any 
result with P<0.05 was considered statistically significant. 
 
2.6.3.1. Incidence rate 
The incidence rate of pregnancy was calculated as number of pregnancies per 100 
woman-years of follow up, i.e. calculated as number of new pregnancies/total woman-
years of follow up multiplied by 100.  
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2.6.3.2. Survival time analysis 
For this analysis, pregnancy test results were categorised into a binary outcome. Time 
to first positive pregnancy test after enrolment was defined as time to failure and data 
were set to survival time data. A survival analysis of cumulative probability of having the 
outcome at any one point in time and the median time to occurrence of the outcome 
was conducted. The Kaplan Meier survival analysis was used to determine the time to 
first pregnancy. These results were plotted on a Kaplan Meier curve and groups 
(hormonal compared to barrier method, injectable compared to oral contraception) 
compared by the log rank test. 
 
2.6.3.3. Univariate Analysis 
The hazard rate for pregnancy was calculated using a Cox regression model. Cox 
regression allowed for analysis of time-varying outcome variables in a prospective 
cohort study design. 
A univariate analysis for each potential confounder was done and hazard ratios with p 
values of less than 0.15 for each confounder were then included in the multivariate 
model. 
 
2.6.3.4. Multivariate Analysis 
Variables with a p value of 0.15 on Cox univariate analysis were individually added into 
the final multivariate Cox regression model, observing changes in hazards ratios to 
assess for potential confounders. Variables that were considered for inclusion into the 
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model were age, level of education, religion, employment status, type of contraception 
and type of partner. 
 
2.7. Ethical Considerations 
The protocol and consent forms for the primary study were approved by the University 
of the Witwatersrand Human Research Ethics Committee (HREC) and the protocol for 
secondary data analysis was reviewed and approved by the HREC, reference 
M090467. All participants signed informed consent in their preferred language (isiZulu, 
seSotho or English). Consent was confirmed verbally at each follow up visit. To 
maintain confidentiality, participant records and results were only identified by unique 
identifiers and not by participant name. Participants who were diagnosed with a STI 
were treated at the study site and those who fell pregnant or who acquired HIV were 
referred to health facilities close to where they lived for further care. 
Participants were not paid for participation in the trial but were re-imbursed for transport 
costs for each visit attended. 
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3. RESULTS 
3.1. Participants 
Between October 2005 to August 2008, 2508 women were enrolled in the MDP301 trial. 
Figure one illustrates the flow of participants that were included or excluded in this 
analysis. Participants that contributed at least one follow up visit were included in this 
analysis. Of the 2508 enrolled participants, 2489 were included in the description of 
baseline characteristics and 2437 were included in the survival analysis. The main 
reasons for exclusion were women who did not attend a follow up visit. Of the 2437 
patients included in the survival analysis, 238 (10%) participants became pregnant 
during their period of follow up. Of the 2437 participants included in the survival 
analysis, 2171(hormonal contraception and barrier method users) were included in the 
multivariate analysis  
 
3.2. Missing data 
Of the 337 participants who did not contribute to the multivariate analysis, 266 were 
using methods of contraception other than a barrier method or a hormonal 
method(IUCD, tubal ligation and traditional methods), 5 participants were missing data 
on the type of contraception used at follow up, 47 only contributed data for the 
enrolment visit and 19 were co-enrolments in other HIV prevention trials (or between the 
RHRU’s two clinical sites). The demographic features of those excluded from the final 
analysis were similar to those of the main cohort. The median age was 31 SD (10) 
years, 317(84%) were unemployed and 213(57%) Christian At the time of data 
extraction, 1 236 participants were still in follow up (and so did not contribute a full year 
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of follow up) and 209 had stopped participating in the trial early. Of the 209 that stopped 
participation in the trial, 23/209 (11%) had relocated, 22/209 (11%) withdrew consent for 
various reasons, 3/209(1%) withdrew when 2% arm of the gel was discontinued, 3/209 
(1%) died and 158/209 (76%) were lost to follow up. None of those who withdrew 
consent were because of pregnancy.  
Data from women who prematurely withdrew from the study or who were lost to follow 
up were censored on the date of the last pregnancy test result. 
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Figure 1: Flow of participants enrolled in the MDP trial, Johannesburg 2005 - 
2008, from screening to inclusion in the final analysis 
Women screened 
3828 
Ineligible at Enrolment 114 (3%)  
Clinical (Grade 3 lab/clinical abnormalities and 
cervical lesions) 77 (2%) 
Other 37 (1%) 
Women enrolled  
2508 
Ineligible at Screening 850 (22%) 
HIV positive 679 (18%) 
Pregnant 110 (3%) 
0ther 61 (2%) 
Did not come back for enrolment  
356 (9%) 
52 excluded from analysis due to:  
Did not attend one follow up visit 47  
Missing data on contraception at follow up 5 
 
Included in survival analysis  
2437 
Included in analysis for description of 
baseline characteristics 
2489 
Excluded from analysis due to  
Co - enrollment 19 
Included in multivariate analysis 
2171 
(Barrier method and hormonal contraception users) 
266: No contraception or using other 
contraception other than hormonal or barrier 
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3.3. Descriptive data 
The baseline demographic characteristics of the participants enrolled were compared in 
two groups, those who became pregnant and those who did not become pregnant (table 
3.1). With the exception of age, where women who became pregnant were younger 
than those who did not, the two groups were similar with respect to demographic 
characteristics. The mean age of women participating in the study was 27.30 (SD 8) 
years. The majority of enrolled patients 1269/2489 (51%) were between 18 and 24 
years. The reported rates of contraception use at enrolment were high, 94% 
(2333/2489) of women reported using contraception; with the majority 55% (1373/2489) 
reporting hormonal contraception use. Barrier methods were more commonly used by 
women who became pregnant than those who did not fall pregnant 59% (140/239) and 
32% (712/2250) respectively p<0.001. 
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Table 3 1: Baseline characteristics of women in the MDP trial: comparing those 
who became pregnant during the study and those who did not become pregnant, 
Johannesburg 2005 to 2008 
 
All women 
N (%) 
2489 
Did not become 
pregnant 
 N (%) 
2250 
Became 
 pregnant N (%) 
239 
P- value 
Age 
    
18-24 1269(51) 1126(50) 143(60) <0.001 
25-34 770(31) 694(31) 76 (32)  
>35 450 (18) 430(19) 20(8)  
Level of Education 
    
No Education 87(3) 85(4) 2(1) 0.191 
   Completed Primary  
    School 
1317 (53)  
1191 (53) 
 
126 (53) 
 
   Completed Secondary  
 School 
1036 (42)  
931 (41) 
 
105(44) 
 
  Completed a tertiary 
    Qualification 
 
49(2) 
43 (2) 6(2)  
Employment Status 
    
  Not Employed 2146 (86) 1935(86) 211(88) 0.34 
  Employed 343(14) 315(14) 28(12)  
Type of Contraception Used 
    
No contraception 156(6) 141(6) 15(6) <0.001 
Barrier Method 852(34) 712(32) 140(59)  
Hormonal  1373(55) 1289(57) 84(35)  
Other( IUCD and  
Sterilized) 
108(4) 108(5) 0  
Religion 
    
None 312 (12) 277 (12) 35 (15) 0.23 
Christian 1419 (57) 1296 (58) 123 (51)  
Zionist 365 (15) 330 (15) 35 (15)  
Other 393 (16) 347 (15) 46 (19)  
Type of Partner 
    
   Long term stable 2437 (98) 2202 (98) 235 (98) 0.64 
   Casual partner 52(2) 48( 2) 4( 2)  
 33 
3.4. Pregnancy incidence and survival time 
The 2437 enrolled women included in the analysis provided 2248 woman-years of 
follow up. A total of 238 incident cases of pregnancy were recorded in this group. One 
pregnant participant was excluded from the analysis because she did not have data on 
contraception at follow up. Three of the women had two pregnancies each. The overall 
pregnancy incidence was 11 per 100 woman-years of follow up (95% CI: 9.32 to 12.02). 
The incidence rate of pregnancy was highest in the last 3 months of follow up, 98 per 
100 woman-years of follow up (95% CI: 85.09 to 112.35) compared to 2 per 100 
woman-years of follow up in the first 3 months (95% CI: 0.94 to 2.92) (table 3.2 and 
figure 2).  
 
 
Table 3.2 Pregnancy incidence rates at 3 monthly intervals of follow up, in women 
enrolled in the MDP trial, Johannesburg 2005-2008. 
Follow up time 
period (months)  
Incident 
pregnancies  
Woman-years 
of follow up  
Incidence rate  
(per 100 woman-
years) 95% C I 
0–3 12 724 1.66 0.94 - 2.92 
3-6 18 693 2.6 1.64 - 4.12 
6-9 9 628 1.43 0.75 - 2.76 
9-12 199 204.07 98 85.09 - 112.35 
Total 238 2248.07 10.590 9.32 - 12.02 
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Table 3.3 shows pregnancy incidence rates and unadjusted incidence rate ratios of 
pregnancy by type of contraception used during follow up. The incidence rate of 
pregnancy was higher in those women using barrier methods of contraception, 11 per 
100 woman-years of follow up (95% CI: 7.78 to 14.34) compared to those women using 
hormonal contraception, 7 per 100 woman-years of follow up (95% CI: 6.07 to 8.72). 
Relative to barrier method users, the incidence rate ratio of pregnancy was lower in 
those who reported hormonal contraception use 0.69(95% CI: 0.48 to 0.91, p= 0.045). 
 
Table 3.3 Incidence rates for pregnancy by type of contraception used (hormonal 
compared to barrier method) at follow up in women enrolled in MDP trial, 
Johannesburg, 2005-2008  
 
 
For those women who used hormonal contraception, there was no difference in 
pregnancy incidence rates between oral contraception and injectable contraception 
users, 8 per 100 woman-years (95% CI: 5.78 to10.67) and 7 per 100 woman-years 
(95% CI: 5.59 to 8.76) respectively. The rate ratio of pregnancy was lower in those 
using injectable contraception, 0.89 (95% CI: 0.60 to 1.34) but this result was not 
significant (p = 0.54) (table 3.4). 
Type of 
contraception 
Incident 
pregnancies 
N 
Woman years 
to follow-up 
Incidence per 100 
woman years (95% CI) 
Rate Ratio p-
value 
Barrier Method 41 388 11 (7.78 - 14.34) 1 0.045 
Hormonal 117 1608 7 (6.07 - 8.72) 0.69 (0.48 – 0.91)  
Total 158 1996 8 (6.77 – 9.25)   
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Table 3.4: Incidence rates for pregnancy by type of hormonal contraception used 
at follow up in women enrolled in MDP trial, Johannesburg 2005 - 2008 
 
Type of 
contraception 
Incident 
pregnancies 
Woman 
years to 
follow-up 
Incidence per 
100 woman 
years(95%CI) 
Rate Ratio relative 
to oral P value 
 
Oral 41 522 8 (5.78 – 10.67) 1 0.548 
 
Injectables 76 1086 7 (5.59 - 8.76) 0.89 (0.60 - 1.34)  
Total 117 1608 7 (6.07 - 8.72)   
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3.5. Survival time outcomes 
The Kaplan Meier curve in figure 2 illustrates the survival time to first pregnancy in the 
2437 participants that were included in the analysis. 
 
Figure 2: Kaplan Meier curve for survival to first pregnancy at follow up in women 
enrolled in a microbicide trial, Johannesburg 2005-2008  
 
The Kaplan Meier curves for survival time to pregnancy comparing, firstly, any hormonal 
contraception to barrier methods and secondly, injectable contraception to oral 
contraception, are illustrated in figures 3a and 3b respectively. The log rank test for 
equality showed a significant difference in survival time to pregnancy in participants 
using barrier methods compared to hormonal contraception and no difference in survival 
0.00 
0.25 
0.50 
0.75 
1.00
0 .2 .4 .6 .8 1 
analysis time 
Kaplan-Meier survival estimate 
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time to pregnancy in participants using oral contraception compared to injectable 
contraception (table 3.5). 
 
 
 
Figure 3(a) and 3 (b): Kaplan- Meier curves for survival to pregnancy by type of 
contraception used during follow up in women enrolled in a microbicide trial , 
Johannesburg 2005-2008 
0.00 
0.25 
0.50 
0.75 
1.00 
0 .2 .4 .6 .8 1 
analysis time 
Oral Injectable 
Kaplan-Meier survival estimates, by hormonal contraception 
0.00 
0.25 
0.50 
0.75 
1.00 
0 .2 .4 .6 .8 1 
analysis time 
 Barrier method Hormonal 
Kaplan-Meier survival estimates, by type of contraception  
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Table 3.5 Log rank test for equality of survival times measured for pregnancy in 
women enrolled in MDP trial, Johannesburg 2005-2008 
Variable Expected 
Events 
Observed 
events 
Chi 2 P value 
Type of contraception     
Barrier Method 30.49 41 4.78 0.028 
Hormonal 127.51 117   
Hormonal Contraception     
Oral 39 41 0.23 0.63 
Injectable 78 76   
 
 
 
 
3.6. Univariate and Multivariate analysis of factors associated with 
pregnancy. 
For the analysis comparing hormonal contraception to barrier methods, of the 2171 
participants that reported use of these methods at follow up, 80% (1740 / 2171) were on 
hormonal contraception(table 3.6). 
The univariate analysis for association between type of contraception used and 
pregnancy demonstrated a hazard ratio (HR) of 0.68 (95%CI: 0. 48 to 0.97; p= 0.04). 
There was no significant difference in risk of pregnancy between the hormonal 
contraception (oral vs injectable) users, HR 0.91 (95% CI: 0.63 to 1.33, p=0.64). 
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Age group was the only possible confounder that fitted the criteria for inclusion into the 
multivariate model, p< 0.15. 
Being 35 years and older reduced the risk of falling pregnant during follow up by 47%, 
HR 0.53 (95% C.I 0.31 to 0.92; p=0.024), compared to women who were younger than 
25 years. (table 3.6).. 
When age was included in the multivariate model for the association of type of 
contraception used and pregnancy, the univariate HR of 0.68 (95% CI: 0 .48 - 0.97; 
p=0.04) changed very slightly to an adjusted HR (AHR) 0.66(95% CI: 0.46 to 0.94, 
p=0.02). 
Adjusting for type of contraception used, those who were 35 years and older were 49% 
less likely to fall pregnant compared to those who were younger than 25 years, AHR 
0.51(95%CI: 0.30 to 0.88, p=0.016). 
Education and employment status were not associated  with pregnancy risk.  
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Table 3.6 Univariate and multivariate analysis results for factors associated with 
pregnancy at follow up in women enrolled in MDP trial, Johannesburg 2005-2008  
  
Univariate analysis Multivariate analysis 
 
Hazards  Ratio 
(95% confidence interval)  
P value  Hazard  Ratio 
(95% confidence interval)                      
P 
value
Age 
    
18-24 1  1  
25-34 0.80(0.56 - 1.13) 0.20  0.81 ( 0.57 - 1.14) 0.24 
>35 0.53( 0.31 - 0.92) 0.024  0.51 (0.30 - 0.88) 0.016 
Contraception  Type 
     
Barrier  1  1  
Hormonal  0.68(0 . 48 - 0.97) 0.04  0.66(0.46 - 0.94) 0.02 
Level of Education 
     
   Primary education 
   orl less 
1    
   Completed  
   Secondary school 
1.19 (0.92 -1.54) 0.17   
Employment Status 
     
Unemployed 1    
Employed 0.92 (0.57 - 1.49) 0.74    
Religion 
     
None 1    
Christian 0.86(0 .55 - 1.35) 0.50   
Zionist 0.71 (0 .38 - 1.30) 0.30   
Other 0.94 ( 0.54 - 1.62) 0.81   
Type of Partner 
     
Casual partner 1    
Stable/long term 
 Partner 
1.18( 0.38 - 3.70) 0.78   
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3.7. Test for the assumptions of a Cox regression model 
The assumption of a Cox regression model is that, the proportion of hazards is constant 
over time. A test for this assumption was done in STATA® version 10. The observed 
Kaplan Meir survival curves were close and parallel to the Cox predicted curves, 
illustrating that the assumption was not violated( figure 4) 
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Figure 4. Test for assumptions of Cox regression Model applied to Cox model for 
the assessment of risk in women enrolled in MDP trial, Johannesburg 2005 to 
2008. 
 
 
 42 
4.  DISCUSSION 
 
This analysis revealed a significant difference in pregnancy incidence rate between 
women who used hormonal contraception and those who used barrier methods. 
Relative to barrier method users, women on hormonal contraception had a significantly 
decreased risk of falling pregnant. However, there was no significant difference in 
pregnancy incidence rates between women who used injectable contraception and 
those who used oral contraception. In addition younger age was associated with 
incident pregnancies. The incidence of pregnancy increased with increasing time of 
participation in the trial, with highest pregnancy incidence recorded in the last 3 months 
of follow up. 
 
At baseline there was no significant difference in demographic features between those 
who became pregnant during follow up and those who did not. A high proportion of 
women reported contraception use in both groups. Hormonal contraception was the 
most common method of contraception (53%) used, followed by condom use (34%). 
This finding was similar to other HIV prevention trials5,6. In contrast, the two SAVVY 
trials36,11 and the CS10 trial reported higher proportions of participants using condoms 
than hormonal contraception (71% vs 9%; 47% vs 14% and 56% vs 17%) respectively. 
The possible explanation for this difference is that this study only included women from 
South Africa, where contraception is easily available and recruitment activities focused 
on family planning clinics. 
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4.1. Pregnancy incidence 
The study found that the overall pregnancy incidence was 11 per 100 woman-years of 
follow up (95% CI: 9.32 to 12.02) This was similar to the pregnancy rates reported in 
some of the HIV prevention trials: 13.2 per 100 woman-years in the HPTN 039 trial 15 
and 11.3 per 100 woman-years in the HPTN 035 trial8. However, much higher incidence 
rates were reported in some trials. The Ghana SAVVY trial reported pregnancy 
incidence rates of 42.5 per 100 woman years and 43.7 per 100 woman years in the 
SAVVY and placebo groups respectively11. Incidence rates as high as 52 per 100 
woman-years reported in the FHI Tenofivir Disoproxil Fumarate trial12. One possible 
explanation for the difference in pregnancy incidence in these trials could be that both 
the SAVVY and the FHI trials reported a higher proportion of women using condoms as 
compared to hormonal contraception. The other explanation could be that the FHI 
Tenofivir trial recruited women with multiple partners and therefore could have engaged 
in a higher number of sex acts.  
 
This study showed that there was an increase in pregnancy rates with increasing 
duration of study participation. The incidence rate of pregnancy was highest in the last 3 
months of follow up, 98 per 100 (95% CI: 85 to 112) woman-years of follow up. One 
possible explanation for the increase in pregnancy incidence rates with increasing time 
could be due to changes in a woman’s desire to have children during the study period. 
Also because of the fact that participants were counseled against pregnancy during 
follow up, they might have planned to attempt pregnancy later in the trial with the hope 
that they would only conceive after the year’s participation in the trial was completed. It 
is also possible that the intensity of counseling messages decreased with increasing 
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duration of participation in the trial, with the participants who were perceived to be 
adherent to study requirements receiving fewer, less focused counseling messages on 
contraception or staff spending less time on counseling.  
 
The results of this study also showed that there was a difference between pregnancy 
incidence rates in women who reported hormonal contraception use at follow up 
compared to those on barrier methods. However, there was no significant difference in 
pregnancy incidence between the two types of hormonal contraception (oral vs 
injectable) users. This is contrary to other studies that have reported substantially 
increased protection from non-user dependent methods, such as injectable 
contraception methods, compared to oral contraception 28,15. This maybe due to good 
counseling on adherence. 
 
Because information on change in contraception use was not analysed and because not 
all participants received contraception at the study site, it is possible that adherence 
was not good even in those who reported non user-dependent methods. This highlights 
the importance of having systems to monitor adherence to contraception use. 
 
4.2. Factors associated with pregnancy 
This study found that hormonal contraception use reduced the risk of falling pregnant. 
The association between the types of contraception used at follow up was significant at 
univariate level, with women on hormonal contraception being 32%, (HR 0.68, CI: 0. 48 
- 0.97) less likely to fall pregnant compared to those who used barrier methods. After 
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controlling for age, the risk of falling pregnant in those who used hormonal 
contraception, at follow up, was further reduced to 34% less, AHR 0.66 (95% CI: 0.46 to 
0.94, p=0.02), compared to those who used barrier methods. The association between 
age and hormonal contraception supports findings from other HIV prevention 
studies15,28. 
 
In univariate and multivariate analysis there was decreased pregnancy incidence with 
increasing age. In univariate analysis women aged 35 years and older had 47% (HR 
0.53; 95% CI: 0.31 to 0.92; p=0.024) less risk of falling pregnant compared to women 
younger than 25 years. This association remained significant after controlling for type of 
contraception used. This finding was similar to those from other studies15;16;38;40. 
 
There was no association between level of education and risk of falling pregnant. This is 
contrary to what has been reported in literature where education was protective. A 
sensitivity analysis, looking at completed secondary education as a reference was 
conducted; this analysis did not change the result. 
 
 
4.3. Strengths of the study 
A prospective cohort study is a good study design to estimate incidence of a common 
outcome such as pregnancy in HIV prevention trials. The study has a large sample size, 
which allowed estimation of tight confidence intervals. For example, the confidence 
intervals around the pregnancy incidence is narrow in this analysis, suggesting that the 
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true pregnancy incidence lies between 9.32 and 12.02 per 100 woman-years, which is 
very close to 11 per 100 woman-years of follow up. Overall follow up was good (91%) 
which resulted in a high number of woman-years to follow up, again allowing for 
accurate estimates of effect. 
Additional strengths of this study included the use of consistent and standardised 
enrollment and data collection protocols that occur within the context of clinical trials 
with adequate resources. Pregnancy testing was done regularly and consistently, the 
screening pregnancy test is sensitive and the confirmatory test was done in a laboratory 
setting and is considered very specific. This allowed accurate estimation of the outcome 
variable. 
 
4.4. Limitations 
 
4.4.1. Definition of exposure 
For the analysis, a change in type of contraception used was not considered and the 
duration of time on a particular type of contraception was not analysed. Since not all 
participants who reported hormonal contraception use received contraception at the trial 
site, it was not possible for the investigators to accurately verify information given by 
participants about contraception use. Also condom use was self reported and the 
analysis to determine how often these were used was not done. There was no biological 
assessment for confirmation of hormonal levels to measure consistent use of hormonal 
contraception. 
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4.4.2. Other limitations 
The data for the analysis was extracted before the end of the trial and this led to a 
decrease in the number of participants contributing a complete year of follow up. This 
could have underestimated the pregnancy incidence. 
Contribution to time off product due to pregnancy was not analysed, therefore it was not 
possible to assess whether pregnancy in this cohort contributed to a significant amount 
of time off product use and so how this may have affected the power of the study to 
detect a difference in the three arms of treatment. 
The analysis was limited to participants using hormonal and barrier method of 
contraception, this meant that the full set of reasons for pregnancy were not explored.  
 
4.4.3. Possible sources of bias 
Selection bias might have been introduced because participants volunteered to 
participate in the trial and those who chose to participate might have been 
systematically different from those who chose not to participate. 
The study focused recruitment activities at family planning clinics, so the results may be 
biased towards people with access to family planning and who therefore have a higher 
proportion of hormonal contraception users than the general population. 
Loss to follow up although low (10 %), may have introduced bias during the trial leading 
to an underestimation of the pregnancy incidence rate. Women who were lost to follow 
up may have been different to those who remained in follow up, with a likely scenario 
that women who knew they were pregnant may not have returned to the study as all 
participants were counseled about the investigators’ concerns around pregnancies.  
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4.4.4. Possible source of confounding 
Possible confounders included age, religion and level of education. Information on these 
was collected by structured interviews during the trial and these were controlled for 
during the analysis by the regression model. 
This was a secondary data analysis, thus data on variables that are important such as 
information on parity and whether participants were married or cohabiting was not 
collected as part of the main trial and these could not be analysed or controlled for in 
the analysis. Other studies reported increased hormonal contraception use in married 
women compared to single women. Kibuuka et al3 reported that married women were 
more likely to use hormonal contraception compared to single, separated or widowed 
women OR 3.3 (95% CI: 1.34 to 7.93) and were less likely to use condoms OR 0.3 
(95% CI: 0.12 to 0.97).  
 
4.5. Conclusion 
Even though there is limited published data on factors associated with pregnancy in HIV 
prevention trials, this study corroborated previous findings with regards to the 
significance of hormonal contraception use and participant’s age as factors associated 
with pregnancy. 
Despite hormonal contraception use being protective, there was still a significant 
number of participants that became pregnant who had reported using these methods at 
follow up. In reality, reported contraception use does not necessarily translate into 
prevention of pregnancy. Provision of contraception by the trial site may improve 
adherence and lead to more consistent use, as trial staff may well have more time to 
counsel women than staff in a busy primary health care clinic.  
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Focus group discussions and or interviews with a sample of participants who become 
pregnant and those who do not become pregnant in the trials could provide valuable 
information for better understanding of additional factors associated with pregnancy. 
 
While testing of investigational products in pregnancy is still being considered, HIV 
treatment and prevention trials will need to consider innovative measures to improve 
access to reliable contraception and to ensure regular and, more importantly, persistent 
use of reliable methods to prevent the pregnancies that may occur later in the trial as 
happened in the MDP301 trial. This may include specific counseling sessions for 
women in the second part of the year’s participation, group sessions on contraception 
and pregnancy. The innovative use of technology, such as videos, may help to 
decrease the load of this additional counseling on study staff. Particular attention should 
be focused on women who are younger than 25 years and using condoms as the only 
method of contraception.  
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